About this trial
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS).
Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE.
The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients with systemic sclerosis (ACR-EULAR Criteria)
Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
Patients consenting to participate to the study
Patients enrolled in the national healthcare insurance program
Disqualifiers
Patients/Healthy volunteers under 18 years old
Patients/Healthy volunteers protected by the law
Patients/Healthy volunteers not consenting to participate to the study after information
Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion
Trial population
Group 1 : Adult with SSc Group 2 : Adult with other connective tissue disease Group 3 : Healthy adult volunteer
Trial design
Other
Prospective
Treatments tested in this trial
Blood sample
Other interventionBlood sample to quantify and qualify NETosis in vivo and ex vivo after different stimulations.
Treatment groups
Trial outcomes
Primary outcomes
Quantification of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, SLE and healthy controls.
Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used.
Secondary outcomes
Analysis of the composition of Neutrophil Extracellular Traps (NETs)
Comparative analysis of the composition of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils in vitro by serum from SSC, other connective tissue diseases and healthy controls. Neutrophils from SSC, other connective tissue diseases and healthy subjects will be used.
Analysis of the cytokines influencing Neutrophil Extracellular Traps NETs production in vitro
Comparative analysis of the quantity of Neutrophil Extracellular Traps (NETs) generated after stimulation of neutrophils from SSC patients in vitro by differents cytokines
Sponsors and contacts
Click on the lead sponsor to view all of their trials.